Why Micron Stock Fell 17% Last Month
Key PointsTech investors grew increasingly worried that companies are spending too much on AI.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
What's breaking now, across thousands of outlets.
Key PointsTech investors grew increasingly worried that companies are spending too much on AI.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
These ETFs are evergreen buys, and they're strong candidates for long-term holds.
Panama and Costa Rica drove a subscriber rebound while buybacks ramped up.
Plus, news about Immunovant, Abeona Therapeutics, Ellodi Pharmaceuticals, Spruce Biosciences, Adrenyx Biosciences, Edesa Biotech, Kyorin Pharmaceutical, Charles River Laboratories, Frontage, Compass…
Synergy capture lifted margins, though fourth-quarter revenue is expected to slip.
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
Gross margins are climbing into the low 40% range, a sign that full-price selling power is holding despite rising costs.